alexa HLA-DR, HLA-DQ Haplotypes and Diabetic Autoantibodies in Nondiabetic Siblings of Type I Diabetes | OMICS International
ISSN: 2155-6156
Journal of Diabetes & Metabolism
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

HLA-DR, HLA-DQ Haplotypes and Diabetic Autoantibodies in Nondiabetic Siblings of Type I Diabetes

Sitelbanat Awadalla1* and Manan AL Hakbany2

1Department of Basic clinical Sciences, College of Medicine, King Saud Bin Abdelaziz University, Riyadh, Saudi Arabia

2Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Corresponding Author:
Dr. Sitelbanat A Awadalla
Department of Basic Medical Science, College of Medicine
King Saud Bin Abdel Aziz University, National Guard
P.O. Box 22490, Riyadh 11426, Saudi Arabia
Tel: +9661 4291341
E-mail: [email protected]

Received Date: May 16, 2015; Accepted Date: June 29, 2015; Published Date: July 03, 2015

Citation: Awadalla S, AL Hakbany M (2015) HLA-DR, HLA-DQ Haplotypes and Diabetic Autoantibodies in Nondiabetic Siblings of Type I Diabetes. J Diabetes Metab 6:580. doi:10.4172/2155-6156.1000580

Copyright: © 2015 Awadalla S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Diabetes & Metabolism


The screening of non-diabetic siblings of Saudi type 1 diabetes mellitus (T1DM) patients (n=54) and 50 healthy controls was undertaken for glutamic acid decarboxylase (anti-GAD) and antibodies to tyrosine phosphatse (IA-2) using radioimmunoprecipitation. HLA-DRB1, DQB1 and DQA1 alleles were tested by PCR and sequence-specific oligonucleotide probes. HLA analysis showed that susceptible alleles were DRB1*03:01 (61.1%) *04:01 (22.02%), DQA1*05:01 (61.1%), DQA1*03:03 (33.3%) and DQB1*02:01 (72.2%). The DRB1*03:01-DQA1*05:01-DQB1*02:01 haplotype was significantly higher among siblings (61%). The protective alleles were DRB1*04:03 (1.8%), DRB1*13 (11.1%), DQA1*02:01 (5.6%), DQA1*05:05 (5.6%), DQB1*03:01 (5.6%) and DQB1*05:01 (11.1%). GADA (22.2%) and anti-IA-2 (11.1%) were significantly higher among siblings, both antibodies present in 27.8% of siblings. The frequency of GADA was higher in those aged 5 to 10 years (50%), while IA-2 positive children were > 5years old (100%). 36.4 % of DRB1*03:01-DQA1*05:01-DQB1*02:01 sibling were positive for GADA, 18.2% were positive for IA-2 and 9.1% were positive for both antibodies. 27.8% of siblings were HLA-identical to the proband, 61.1% were haploidentical, and 11.1% were not identical. GADA was significantly higher among the HLA-identical siblings (60%) than haploidentical (9.1%) and non-identical siblings (zero). IA-2 was higher in HLA-identical (20%) from haploidentical (9.1%) and non-identical HLA (zero) but not to significant level. Both antibodies were present in 20% of HLA-identical siblings, and in none of the haplo- or non-identical HLA. In conclusion, the immunogenetic screening of nondiabetic sibling identifies individuals at risk of developing T1DM.


GAD; IA-2; Type 1 Diabetes Mellitus ; HLADR ; DQ


Over the last decade, the ultimate goal of diabetes research has focused on a better ability to predict T1DM so as to apply earlier intervention before the appearance of clinical symptoms [1]. Besides, the long subclinical prodromal period before the clinical manifestation of the disease gives an opportunity to identifying those individuals at risk [2]. Data obtained from research on the identification of high-risk individuals proved to be beneficial for intervention trials, and were vital clinically in counseling families with diabetic children [3].

Kulmala et al. [4] found that the analysis of high-risk genetic markers in combination with autoantibodies offers an excellent tool for identifying suitable at risk subjects to enroll in intervention trials. Decochez et al. [5] studied 4,589 Belgian first-degree siblings concluded that combined positivity for DQ2/DQ8 and IA-2 defined the highest risk population for prevention trials. On the other hand, Buczkowska and Chobot [6] suggested that autoantibodies alone in siblings were useful markers for identifying high risk individual for T1DM. Merna et al. [7] reported that, autoantibody status, susceptible alleles, and insulin sensitivity will be useful in assessing the risk of progression to type 1 diabetes in addition, to age and family history of type 1 diabetes at the time of diagnosis of the index.

A subsequent study included a large number of siblings of type I diabetic children (n=701) who were followed for 15 years [8]. This study uncovered the strongest predictive model for progression to clinical disease which included age of sibling at the first sampling, HLA-DR that confer susceptibility, number of autoantibodies detected at the first sampling, and the number of affected siblings with Type 1 Diabetes Mellitus. The study also emphasized the role of IA-2 in the prediction of Type I Diabetes [8]. Numerous other studies have explored the association of DRB1, DQA1, and DQB1 with type 1 diabetes in different ethnic background [9-12]. However, the current study is the first to be undertaken in Saudi Arabia.

Thus the aim of this study is to test Saudi non-diabetic siblings of T1DM and controls for HLA DRB1, DQA1 and DQB1 haplotypes and test them for the presence of anti-GAD65 and anti-IA-2 autoantibodies.

Materials and Methods

Siblings and controls

The studied population composed of 54 non-diabetic sibling of Saudi TIDM. 26 were females and 28 males. Their mean age was 7.5 years at the time of proband diagnosis (range 1-20 years). Healthy controls (n=50) had no family history of T1DM. All particpants were screened for HLA-DRB1, HLA-DQA1, HLA-DQB1 and for autoantibodies against GAD and IA-2. Further, participants or their parents gave informed written consent, and the study was approved by the College of Medicine Institutional Research Board (IRB).

Laboratory assays

HLA genotyping: Total genomic DNA was extracted from the peripheral blood mononuclear leukocytes from siblings and controls using Qiagen Kit (27220 Turnberry Lane, Valencia CA 91355). The HLA-DRB1, DQB1 and DQA1 gene alleles were analyzed by the PCRsequence- specific priming technique, using the Micro SSP™ DNA Typing Trays (one lambda, Inc. 21001 Kittridge Street Canoga Park, CA 91303-2801 USA). The sequence-specific oligonucleotide primers used for the amplification of HLA alleles and the human B-globin gene were used as negative controls. Pre optimized primers were presented (dried) in different wells of a 96-well 0.2 ml thin-walled tube tray to be used for PCR testing and ready for the addition of DNA samples, recombinant Taq polymerase, and specially formulated dNTP-buffer mix (Micro SSP™ D-mix, one lambda). Each tray included a negative control reaction tube that detected the presence of the internal control PCR product generated by the Micro SSP™ DNA Typing Tray. The PCR products were analyzed on a 2.5% (wt/vol) agarose gel stained with ethidium bromide (0.5 μg/ml).

Autoantibodies assays: The antibodies against IA-2 and GAD were quantified using the radio binding assay as described previously [13]. Serum samples were incubated with the antigen in a 1:25 dilution in duplicates, and precipitated with Protein A-Sepharose (Amersham Biosciences, Uppsala, Sweden). The plates were counted in a Microbeta counter, and the results expressed as levels of antibodies calculated in relation to a standard curve. The cut-off limit for positivity corresponding to the 98th percentile of 50 healthy controls was 5.35RU for GAD and 0.43 for IA-2. The specificity of GADA assay was 99% and for IA-2 was 97%, while the sensitivity was 75% for GADA and 60% for IA-2. Inter-assay variation for negative and positive controls was 8% and 14% for GADA and 13% and 11% for IA-2.

Data analysis

HLA haplotype frequencies were calculated by direct gene counting. The statical difference in the HLA haplotype distributions between the siblings and controls were determined using Chi-square test (X2) test with Yates’ correction (two-tailed). The odds ratio (OR) and 95% confidence interval were calculated using the Woolf formula to assess the susceptibility effect of the HLA DRB1 and DQB1 alleles and haplotype [14]. The Fisher’s Exact Test was used when the expected frequency for the haplotype was less than five. A p of value <0.05 was considered statistically significant. Correlation between DRB1, DQA1 and DQB1 frequencies and age at the onset were analyzed using the Chi-square test. Statistical analysis was performed using SPSS 22.1 for Windows (SPSS, Chicago, IL).


HLA frequencies among siblings of T1DM patients and controls

HLA-DR: The commonest allele among siblings was DRB1*03:01 (Table 1). The frequency of DRB1*03:01 (61.1%) was significantly higher in siblings compared to controls (16%) (X 20.27, P=0.0001, OR=8.25, 95% CI 2.98-23.56). DRB1*04:01 was significantly higher in siblings (22.1%) than controls (2%) (X7.95, p=0.005, OR14, 95% CL 1.75-2.708). The DRB1*04:03 (1.8% versus 16%) and DRB1*13 (11.1% versus 34%) were significantly lower among siblings than controls (X 3.9, p=0.04, OR 0.12, 95% CI 0.005-0.989), (X 6.6, p 0.01, OR 0.243, 95% CI 0.076-0.747) respectively.

DRB1 allele Siblings         n=54 (%) Controls
n=50 (%)
X2 P value OR CI
DRB1*01 6 (11.1) 10 (20) 0.97 0.33 0.5 0.38-8.12
DRB1*03 33 (61.1) 8 (16) 20.27 0.0001 8.25 2.98-23.56
DRB1*04 25 (46.29) 17 (34) 1.16 0.28 1.67 0.65-3.72
*04:01 12 (22.2) 1(2) 7.95 0.005 14 1.75-2.708
*04:02 1(1.8) 2(4) 0.05 0.95 0.45 0.02-2.77
*04:03 1(1.8) 8 (16) 3.9 0.04 0.12 0.005-0.989
*04:04 2(3.7) 1(2) 0.00 1.00 1.07 0.186*6.03
*04:05 8 (11.1) 1 (2) 2.36 0.12 4.17 0.76-30.18
*04:06 1(1.85) 3(6) 4.6 0.03 0.17 0.03-0.87
DRB1*13 6 (11.1) 17 (34) 6.6 0.01 0.243 0.076-0.747
DRB1*14 1(1.8) 4 (7.4) 1.0 0.32 0.22 0.03-1.50
DRB1*15 15 (27.8) 10 (20) 0.49 0.48 1.54 0.63-3.77
DRB1*03:01/03:01 12 (22.2) 1(2) 7.95 0.005 14.0 1.76-300.26
DRB1*03:01/04:05 8(14.8) 1(2) 3.89 0.04 8.5 1.0-188.79

Table 1: DRB1 distribution among Siblings of T1DM and Control Subjects.

The DRB1*03:01 homozygote haplotype was significantly higher in siblings (22.2%) compared to controls (2%) (X 7.95, p 0.005, OR 14.0, 95% CI 1.76-300.26). The DRB1*03:01-04:05 haplotype was significantly higher in siblings (14.8%) compared to controls (2%), (X 3.89, p 0.04, OR 8.5, 95% CI 1.0-188.79).

DQA1: The DQA1*03:03 (33.3%versus 6%) and DQA1*05:01 (61.1% versus 26%) were significantly higher in siblings than controls (X 10.4, p= 0.001, OR 7.83 95% CL 1.96-36.44), (X11.59 p=0.001, OR 4.47, 95% CL 1.95-10.24) respectively (Table 2). The DQA1*02:01 (5.6% versus 54%) and DQA1*05:05 (5.6% versus 14%) were significantly lower in siblings than controls (X 27.37, p=0.0001, OR 0.05, 95% CL 0.2-0.17), (X 11.75, p=0.001, OR 0.11, 95% CL 0.03-0.39) respectively.

DQA1 Siblings
n= 50(%)
X2 P Values OR 95% CI
*01:01 6(11.1) 2(4) 0.98 0.32 3.0 0.6-13.5
*01:02 18 (33.3) 13 (26) 0.36 0.54 1.4 0.62-3.2
*01:03 3 (5.6) 8 (16) 1.99 0.16 0.31 0.08-1.15
*01:05 1(1.8) 2(4) 0.005 0.95 0.45 0.05-3.59
*02:01 3(5.6) 27(54) 27.37 0.0001 0.05 0.2-0.17
*03:01 9 (16.7) 12 (24) 0.47 0.45 0.63 0.24-1.6
*03:03 18 (33.3) 3 (6) 10.40 0.001 7.83 1.96-36.44
*04:01 3 (5.6) 1(2) 0.19 0.66 2.88 0.39-20.7
*05:01 33 (61.1) 13 (26) 11.59 0.001 4.47 1.95-10.24
*05:05 3 (5.6) 7 (14) 11.75 0.001 0.11 0.03-0.39
*02:01 39 (72.2) 15(30) 16.8 0.0001 6.06 2.6-14.08
*03:01(7) 3(5.6) 13 (26) 6.83 0.009 0.16 0.05-0.59
*03:02 (8) 12 (22.2) 10 (20) 0.001 0.971 1.14 0.45-2.88
*04:02 9 (16.7) 5 (10) 0.51 0.47 1.8 0.58-5.5
*05:01 6(11.1) 18 (36) 7.7 0.005 0.22 0.08-0.62
*06:02 21 (38.9) 23 (46) 0.28 0.59 0.74 0.34-1.62
18(33.3) 6(12) 5.51 0.019 3.67 1.2-11.65
DRB1*03:01-DQA1*05:01-DQB1*02:01 33 (61) 13(26.7) 11.6 0.001 4.47 1.9-10.2

Table 2: The frequency of HLA-DQA1, DQB1 haplotype among siblings of T1DM and controls.

DQB1: The DQB1*02:01 was significantly higher in siblings (72.2%) than controls (30%). (X16.8, p=0.0001, OR 6.06, 95%CL 2.6- 14.08). The DQB1*03:01 (5.6% versus 26%) and DQB1*05:01 (11.1% versus 36%) were significantly lower in siblings compared to controls (X6.83, p=0.009, OR 016, 95%CL 0.05-0.59), (X7.7, p=0.005 OR 0.22, 95% CL 0.08-0.62) respectively.

The homozygote DQB1*02:01 (33.3%) was significantly higher in siblings than controls (12%) (X5.51, p=0.019, OR3.67, 95% CL 1.2- 11.65). The DQA1*05:01-DQB1*0201 haplotype was also significantly higher among sibling (61%) compared to controls (26.7%) (X11.6, p=0.001, OR 4.47, 95%CL 1.9-10.2).

The genotype of siblings of T1DM patients

The DRB1*03:01-DQA1*05:01-DQB1*02:01 genotype was significantly higher in siblings (61.1%) compared to controls (26%) (X 11.89, p= 0.001, OR= 4.47; 95%CL 1.79-11.31). The homozygote DRB1*03:01-DQA1*05:01-DQB1*02:01 was significantly higher in siblings (22.2%) compare to controls (2%) (X 7.95, P=0.005; OR=14, 95% CL 1.76-300.2).

The frequency of anti-GAD and anti-IA-2 among Sibling of T1DM patients

Twelve siblings were positive for anti-GAD (22.2%) significantly higher compared controls (zero) (p=0.001). Six were positive for anti- IA-2 (11.1%) (p=0.015) significantly higher compared to none of the controls. Three siblings (5.6%) were positive for both GADA and IA-2 antibodies (Table 3). The frequency of GADA was higher in the age group 5 to 10 years (50%), while all IA-2 positive were under the age of 5 years (100%).

15 (27.8%)
HLA-un identical
X2 Pc value OR 95% CI
GADA+ve 9 (60%)* 3 (9.1%) 0 11.66 0.001 15 3.3-67.8
IA-2+ve 3(20%) 3 (9.1%) 0 6.34 0.55 2.5 0.5-12.6
IA-2 +ve
3 (20%)* 0 0 7.04 0.008 inf 1.9-inf

Table 3: The relation between HLA sharing with affected proband and autoantibodies in siblings of T1DM patients.

Antibodies correlation with HLA sharing

27.8% of siblings were HLA-identical to the proband, 61.1% were haploidentical and 11.1% were nonidentical. GADA frequency was significantly higher (60%) among the HLA-identical siblings than among the haplo (9.1%) or non-identical siblings (zero) (p=0.001). The frequency of IA-2 was higher in HLA-identical (20%) compared to haploidentical (9.1%) and nonidentical (zero) (Table 3). For multiple antibodies, the presence of two antibodies was significantly higher among HLA-identical siblings (20%) (p=0.008) than haplo and nonidentical siblings (zero). 36.4% of siblings with DRB1*03:01- DQA1*05:01-DQB1*02:01 were positive for GADA, 18.2% were positive for IA-2 and 9.1% were positive for both antibodies.


The aim of this study was to screen non-diabetic siblings of type 1 diabetic Saudi for HLA gene and autoantibodies at the time of proband diagnosis. This study meant to provide a genetic and immunological basis for understanding the mechanisms leading to islet beta-cell destruction among nondiabetic sibling in Saudi population. It is also allowing us to establish markers to identify high-risk individuals for the intervention trials. Genetic studying of siblings of T1DM gives vital clues to the mechanisms of the disease, as the risk of developing the disease was up to 80% in sibling [15].

Identification of a unified genetic risk marker was complicated by the fact that the frequencies of susceptible and protective alleles vary widely across different ethnic groups and geographical regions [16]. Thus, type 1 diabetes risk markers should individually selected for the target population since the efficiency of screening of various markers was highly population-determined.

In the present study, the haplotype DRB1*03:01-DQA1*05:01- DQB1*02:01 was significantly higher among sibling (OR=4.47) compared to controls. A similar association was established before in T1DM Saudi patients as compared to controls [17]. The risk of DRB1*03:01-DQA1*05:01-DQB1*02:01 in the homozygote form was remarkably high (OR=14) among Saudi siblings and compares favorably with similar previously reported frequency in Sardinian patients [12]. On the other hand, DRB1*03:01-DQA1*05:01- DQB1*02:01 was considered a significant risk marker among other Arabs in Bahrain and Lebanon [18].

It has been reported that individuals with two DQB1 (non-Asp) alleles and two DQA1 (Arg) alleles had the highest relative risk for disease, and both were detected in approximately 40% of IDDM patient [19]. Additionally, Dorman and Bunker [20], found that out of the four DQA1 with Arg-52 alleles (DQA1*03:01; *04:01; *05:01, *06:01), only DQA1*03:01 gave a significant contributing independent effect on T1DM risk. In many populations, DQA1*05:01 was also associated with T1DM, and this association was enhanced by the fact that DQA*05:01 was usually inherited with DRB1*03:01 and DQB1*02:01 [21].

Although DRB1*04 was not significantly higher in siblings than controls, some of its subtypes showed a significant difference from controls; for example, DRB1*04:01 was significantly higher in siblings compared to controls, and it has already been established as a marker in Saudi T1DM patients [17] as well as in Belgian [22] and American patients [23]. It is also known that the DRB1*04:03 confers protection against the disease as it found to be higher in controls than siblings; similar result was reported in a previous study on Saudi patients [17]. In the current study the DRB1*04:05 was neutral in siblings, and this finding contrasts the previous report among Saudi T1DM in whom DRB1*04:05 was significantly higher in T1DM patients compared to controls [17].

It is also of interest to add that the positivity to GAD and IA-2 autoantibodies gives satisfactory predictive markers for T1DM in siblings, and even in the general population [24]. Also in the Karlsburge [25] study, from Germany suggested that the combined screening of GADA and IA-2A was enough for the identification of all children at risk for the disease. In support of this, Mrena et al., [7] from Finland emphasized that IA-2 by itself can be a predictive marker in first-degree relatives. Similarly, Decochez et al. [5] from Belgium concluded that IA-2 conferred the highest 5-year diabetes risk (>50%) compared to other autoantibodies (ICA, IAA, GADA), irrespective of the number of autoantibodies present.

The ethnic variation in the prevalence of autoantibodies among T1DM was highlighted in many early studies [26,27]. In the current study, GAD antibody and anti-IA-2 were significantly higher in siblings compared to controls. Similar results of antibodies prevalence were reported in the first-degree relatives from Brazil [28]. In agreement with a report from Finland [29], which found that, GAD antibodies were prevalent more in siblings than ant-IA-2.

Among Saudi nondiabetic siblings, 5.6% were positive for both GADA and IA-2 antibodies. Similar results were reported by Pastore et al. [30], who found 4% of siblings of T1DM patients in Italy were positive for two or more antibodies. Another study considered the frequency of multiple autoantibodies was a more significant marker in disease prediction than the presence of each autoantibody alone [31].

In the present study, when correlating frequencies of antibodies with age, GAD antibody was found to be significantly higher in the age group 5 to 10 years (50%), while all IA-2 positive were under the age of 5years (100%), and this is in line with an earlier report by Kupila A et al. [32].

In reviewing HLA sharing between siblings and proband, we found that 27.8% of siblings were HLA-identical to the proband, 61.1% were haploidentical, and 11.1% were non-identical. A similar result was reported in a study conducted on T1DM siblings from Finland [15].

In the present study, antibodies against GADA were found to be positive in 60% of HLA-identical siblings, and 9.1% in haploidentical siblings and none of the non-identical siblings. In addition, antibodies to IA-2 were positive in 20% of HLA-identical siblings, and 9.1% of haploidentical siblings and none in non-identical HLA siblings. All siblings with multiple autoantibodies were HLA-identical with proband. Similar results were reported before among Russian [33] patients where the prevalence of GAD antibodies was significantly higher in siblings who were identical for one haplotype compared to non-identical siblings. In another Finnish study [34], autoantibody positive children within the same family carry identical HLA-DQB1 genotypes in more than 70% of the cases.

Thus the present finding of our study is that siblings of T1DM were at higher genetic risk than the normal population (controls), and this agrees with similar results from Belgians [35], and in indo-Aryan population in UK [36]. This significant association between HLA gene sharing and the appearance of autoimmune markers in siblings has also been reported among Japanese children and their families [37].

In conclusion, the results obtained in this study showed the importance of immunogenetic screening in the prediction of TIDM. The detection of DRB1*03:01-DQA1*05:01-DQB1*02:01 in 61.1% as heterozygous and 22.2% in homozygous among siblings was considered a genetic risk marker for T1DM among Saudi first-degree siblings. Next are GAD and IA-2 autoantibodies screening which will establish the significant correlation between autoantibodies presence and HLA sharing with their proband. Thus, these findings which were report for first time among Saudi T1DM patients provide a model for establishing an early prediction marker of T1DM among sibling, which we hope will facilitate the early interventional management of the disease.


We were grateful to K. Hamam and J. Chu for their technical assistant. This research supported by a grant from Deanship of Scientific Research, King Saud University.

Conflict of Interest

We wish to confirm that there were no known conflicts of interest associated with this publication. We also confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but were not listed. We further confirm that the order of authors listed in the manuscript has been approved by authors.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Internal Medicine May 21-22, 2018 Osaka, Japan
    May 21-22, 2018 Osaka, Japan
  • International conference on Fitness and Expo June 04-05, 2018 Baltimore, Maryland, USA
    June 4-5, 2018 Baltimore, USA
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Medical and Health Science August 24-25, 2018 Tokyo, JAPAN
    August 24-25, 2018 Tokyo, Japan

Article Usage

  • Total views: 11980
  • [From(publication date):
    August-2015 - Apr 25, 2018]
  • Breakdown by view type
  • HTML page views : 8200
  • PDF downloads : 3780

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version